SCHEMBL29429231

SCHEMBL29429231

c1ccc(-c2cnnnn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.48
GABRG2 P18507 3/20 0.48
GABRB3 P28472 3/20 0.48
GABRA5 P31644 3/20 0.48
GABRA3 P34903 3/20 0.48
RAB9A P51151 5/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
NPC1 O15118 5/20 0.41
ALDH1A1 P00352 4/20 0.41
IDO1 P14902 1/20 0.40
METAP2 P50579 1/20 0.40
KEAP1 Q14145 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL150762 1.00 GABRA1 (0.48) GABRA1GABRG2GABRB3GABRA5GABRA3
Bromide SCHEMBL28568919 0.98 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA5GABRA3
Benzamide SCHEMBL28855712 0.82 CYP2C19 (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL30950412 0.76
SCHEMBL29584431 0.76 GABRG2 (0.51) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12806833 0.72 GABRA1 (0.54) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL151034 0.71 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL21938127 0.71 GABRA1 (0.54) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29516145 0.71 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL23888753 0.71 KDM4E (0.58) RAB9ANPC1ALDH1A1METAP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608454-A1 SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION Eli Lilly and Company (US) 2025-09-03 EP claimed
WO-2025136890-A1 HYDROGEL NANOPARTICLES AS LABELING SCAFFOLD IN SEQUENCING ILLUMINA, INC. (US) 2025-06-26 WO claimed
US-20250197933-A1 HYDROGEL NANOPARTICLES AS LABELING SCAFFOLD IN SEQUENCING ILLUMINA, INC. 2025-06-19 US claimed
WO-2025049700-A1 COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING ILLUMINA, INC. (US) 2025-03-06 WO claimed
US-20250075269-A1 COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING ILLUMINA, INC. 2025-03-06 US claimed
WO-2024092219-A1 SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION ELI LILLY AND COMPANY (US) 2024-05-02 WO claimed
EP-4196581-B1 SEQUENTIAL ENCODING METHODS AND RELATED KITS ENCODIA INC (US) 2026-02-25 EP disclosed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
EP-4684031-A1 POINT OF CARE DIAGNOSTIC METHODS GLIA Diagnostics Pty Ltd (AU) 2026-01-28 EP disclosed
US-20260009068-A1 METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS Encodia, Inc. (US) 2026-01-08 US disclosed
US-12498378-B2 Methods for spatial analysis of proteins and related kits DF PEPTIDE ACQUISITION LLC 2025-12-16 US disclosed
US-12474346-B2 Methods and kits for multicycle encoding assay DF PEPTIDE ACQUISITION LLC 2025-11-18 US disclosed
EP-4646595-A1 PEPTIDE SEQUENCER Oregon Health & Science University (US) 2025-11-12 EP disclosed
US-20220144885-A1 CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES Encodia, Inc. (US) 2022-05-12 US disclosed
WO-2022094148-A1 CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES Encodia, Inc. (US) 2022-05-05 WO disclosed
US-20220127754-A1 METHODS AND COMPOSITIONS OF ACCELERATING REACTIONS FOR POLYPEPTIDE ANALYSIS AND RELATED USES Encodia, Inc. (US) 2022-04-28 US disclosed
US-20220106278-A1 REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS UNIVERSITY OF DELAWARE (US) 2022-04-07 US disclosed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 WO disclosed
EP-3973299-A1 METHODS AND RELATED KITS FOR SPATIAL ANALYSIS Encodia, Inc. (US) 2022-03-30 EP disclosed
EP-3963070-A1 METHODS FOR PREPARING ANALYTES AND RELATED KITS Encodia, Inc. (US) 2022-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144885-A1 CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES TNNI3, CHD1, TNNT2 GABRA1 4504/4885GABRG2 4809/4885GABRB3 4707/4885
US-20260009068-A1 METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS HNRNPAB, ACTB, SSBP1 GABRA1 2763/4885GABRG2 2879/4885GABRB3 1512/4885
US-20220106278-A1 REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS TST, CYP4F8, CYP4Z1 GABRA1 1608/4885GABRG2 1810/4885GABRB3 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.